Publication: Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice.
No Thumbnail Available
Identifiers
Date
2017-11-21
Authors
Gago-Veiga, A B
Santos-Lasaosa, S
Cuadrado, M L
Guerrero, Á L
Irimia, P
Láinez, J M
Leira, R
Pascual, J
Sanchez Del Río, M
Viguera, J
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
OnabotulinumtoxinA has been demonstrated to be effective as a preventive treatment in patients with chronic migraine (CM). Five years after the approval of onabotulinumtoxinA in Spain, the Headache Study Group of the Spanish Society of Neurology considered it worthwhile to gather a group of experts in treating patients with CM in order to draw up, based on current evidence and our own experience, a series of guidelines aimed at facilitating the use of the drug in daily clinical practice. For this purpose, we posed 12 questions that we ask ourselves as doctors, and which we are also asked by our patients. Each author responded to one question, and the document was then reviewed by everyone. We hope that this review will constitute a practical tool to help neurologists treating patients with CM.
Description
MeSH Terms
Botulinum Toxins, Type A
Guidelines as Topic
Humans
Migraine Disorders
Neurologists
Spain
Guidelines as Topic
Humans
Migraine Disorders
Neurologists
Spain
DeCS Terms
CIE Terms
Keywords
Botulinum neurotoxin A, Chronic migraine, Consenso, Consensus, Guidelines, Migraña crónica, OnabotulinumtoxinA, Preventive treatment, Recomendaciones, Toxina botulínica A, Tratamiento preventivo